Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
1255 daily bars · split adjusted
Current price $19.84
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Sep 1, 26 |
Daily · Wilder smoothing
| Mizuho |
| maintain |
| Outperform |
| Outperform |
| Aug 18, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Jun 15, 26 | Mizuho | maintain | Outperform | Outperform |
| May 28, 26 | Guggenheim | maintain | Buy | Buy |
| May 4, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Apr 6, 26 | Guggenheim | maintain | Buy | Buy |
| Mar 26, 26 | HC Wainwright & Co. | maintain | Buy | Buy |
| Dec 22, 25 | HC Wainwright & Co. | maintain | Buy | Buy |
| Nov 20, 25 | Mizuho | maintain | Outperform | Outperform |
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 30.01 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 11.34 | Oscillator | Buy |
| Williams %R (14) | -88.08 | Oscillator | Buy |
| MACD (12, 26, 9) | -1.79 (Hist 0.10) | Oscillator | Buy |
| Average Directional Index (14) | 45.93 (+DI 13.3 / -DI 31.8) | Trend | Strong Sell |
| EMA 20 | 22.08 | MA | Strong Sell |
| SMA 20 | 21.83 | MA | Strong Sell |
| EMA 50 | 24.82 | MA | Strong Sell |
| SMA 50 | 27.36 | MA | Strong Sell |
| SMA 200 | 27.48 | MA | Strong Sell |
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Jun 17, 26 | Bjorkquist Jeanette M | officer: PFO and PAO | S-Sale | 29 @ $23.25 | $674 |
| Mar 29, 26 | Gaggar Anuj | officer: Chief Medical Officer | A-Award | 14,000 | — |
| Mar 29, 26 | White Nicole S | officer: Chief Manufacturing Officer | A-Award | 14,000 | — |
| Jun 4, 26 | Mchutchison John G | director | A-Award | 8,000 @ $24.11 | $192.9K |
| Jun 4, 26 | Mahony Susan | director | A-Award | 8,000 @ $24.11 | $192.9K |
| Jun 4, 26 | Johnson-Pratt Lisa | director | A-Award | 8,000 @ $24.11 | $192.9K |
| Jun 4, 26 | Houghton Michael | director | A-Award | 8,000 @ $24.11 | $192.9K |
| Jun 4, 26 | Consylman Gina | director | A-Award | 8,000 @ $24.11 | $192.9K |
TTM vs. 5-year historical average (annual ratios)
| Metric | ASMB | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 36.1x | -13.3x · sector 20.7x | Elevated |
| Forward P/E (FY26E) | -32.6x | EPS est. -0.61 | Discount |
| Price / Book | 1.2x | 1.4x | In line |
| Price / Sales | 5.4x | 6.2x | In line |
| EV / EBITDA | 5500.3x | -11.4x | Discount |
| Return on equity | -0.0% | — | Weak |
| Gross margin | 77.7% | -95.8% | Below hist. |
| Debt / Equity | 0.01 | 0.05 | Conservative |
| Piotroski / Altman Z | 2/9 | Z 7.38 | Safe zone |
Discounted cash flow model
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| S-8 | Aug 20, 2026 | 2026-08-20 16:30:24 | View |
| SC 13G/A | Aug 14, 2026 | 2026-08-14 16:23:03 | View |
| 8-K/A | Aug 14, 2026 | 2026-08-14 16:05:17 | View |
| 10-Q | Aug 13, 2026 | 2026-08-13 16:15:40 | View |
| 8-K | Aug 13, 2026 | 2026-08-13 16:11:18 | View |
| SC 13G/A | Aug 13, 2026 | 2026-08-13 12:47:33 | View |
| SC 13G/A | Aug 4, 2026 | 2026-08-04 08:29:44 | View |
| 4 | Jun 18, 2026 | 2026-06-18 16:05:04 | View |
| 4 | Jun 5, 2026 | 2026-06-05 17:11:22 | View |
| 4 | Jun 5, 2026 | 2026-06-05 17:10:47 | View |
Proxy statement (DEF 14A) disclosures
Stock news · updated daily
Assembly Biosciences (NASDAQ: ASMB - Get Free Report) and RYTHM (NASDAQ: RYM - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, risk, earnings and dividends. Profitability This table compares Assembly Biosciences and RYTHM's
ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction ABI-6250's pharmacodynamic analysis was recognized as a Poster of Distinction
MSGM, ASMB and MTG made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on September 17th, 2026.
MOV, MAX, MTG, ASMB and MSGM have been added to the Zacks Rank #1 (Strong Buy) List on September 17th, 2026.
SOUTH SAN FRANCISCO, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral and liver diseases, today announced senior management will present during the H.C. Wainwright & Co. 28th Annual Global Investment Conference at 8:30 a.m. Eastern Time on September 16, 2026.
COCO, CHEF, ASMB and CDNA stand out as four defensive picks amid volatility induced by rising oil prices and Middle East tensions.
– Assembly Bio to share 40% of U.S. development costs and profits for helicase-primase inhibitor program for recurrent genital herpes –
The average of price targets set by Wall Street analysts indicates a potential upside of 35.7% in Assembly Biosciences (ASMB). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 13, 2026 | -0.72 | -0.20 | Beat 72.4% | $13.37M |
| May 7, 2026 | -0.73 | -0.54 | Beat 26.0% | $8.21M |
| Mar 19, 2026 | -0.51 | 2.48 | Beat 586.3% | $42.46M |
| Nov 10, 2025 | -0.50 | -0.72 | Miss -44.0% | $10.79M |
| Aug 6, 2025 | -0.65 | -1.33 | Miss -103.6% | $9.63M |
| May 8, 2025 | -2.01 | -1.17 | Beat 41.8% | $9.42M |